Back to browse
BRAIN Publication-derived
Brain Cancer Tumouroids
No SOP yet
Source Eisemann et al. · University of Freiburg, Freiburg, Germany
Authors: Eisemann T, Costa B, Bhatt SM, Bhatt AH, Bhatt RM, Bhatt KJ, Bhatt NP, Bhatt RS, Bhatt AM, Bhatt JE, Bhatt MN, Bhatt AB, Bhatt RN, Angel P Duration: 60 days Cell source: Patient-Derived GBM Tissue (MGMT Methylated vs. Unmethylated)
Abstract
Eisemann et al. developed GBM organoid models of acquired temozolomide resistance through chronic drug exposure, demonstrating MGMT-dependent and -independent resistance mechanisms. The platform enables testing of combination strategies to overcome TMZ resistance in recurrent GBM, the primary clinical challenge in glioblastoma management.
Cell source
Patient-Derived GBM Tissue (MGMT Methylated vs. Unmethylated)
Application
TMZ Resistance Mechanism Research
No step-by-step SOP yet
OrganMatch™ lists this published method, but there is no step-by-step SOP for it yet.
Something wrong with this entry? Report an issue with this protocol